Ilumya(TM) (tildrakizumab-asmn) is a new medication recently approved by the F.D.A. for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

We’ve partnered with patients for nearly 6 years on studies that have helped provide the data to show the outstanding results for patients on this treatment. We are happy to help bring another option to people who live with psoriasis.